#### REMARKS

Applicants provisional generic and species election in response to the Examiners restriction requirement are discussed herein.

### The Restriction Requirement

The Examiner has required restriction of originally filed claims 1-34 of the above-identified application into 14 groups. In response, applicants elect the invention of Group I: "the compounds according to claim 1 of formula I, wherein X is C" without traverse, for further prosecution in this application. In response to the species election requirement, applicants provisionally elect compound 2 (specification page 13) having the following structure:

Pending allowance of claims 1-10 drawn to isoquinolin-1one compounds, applicants request the rejoinder of methods of
treatment claims 22-30 (Groups III, V-VII, and X) pursuant to
MPEP §821.04. Specifically, applicants request that the
method claims that depend from or otherwise include all the
limitations of the patentable product be entered. Applicants

## 13 BEST AVAILABLE COPY

also request the rejoinder of process claim 31 (Group VIII) drawn to preparing isoquinolin-1-one compounds. Additionally, applicants request the rejoinder of compound claim 32 representing compounds of formula IIA (Group XIII), drawn to isoquinolin-1-one intermediates.

Consistent with the above election, applicants have amended the claims, without prejudice, to cancel the non-elected subject matter. The specific amendments are discussed below. Applicants make this election without waiver of their rights to file for and obtain claims directed to the non-elected subject matter in either this application or in divisional or continuing applications claiming priority and benefit from this application under 35 U.S.C. § 120.

#### The Claim Amendments:

Applicants have amended claims 1, 9, 20, 31, and 32 to reflect applicants' election of X=C (isoquinolin-1-ones) in response to the Examiners' restriction requirement. In light of this election, applicants have canceled claims 15-19.

Applicants have amended claims 1, 9, and 31-32 to delete the term "N" from the definition of radical X to remove nonelected subject matter therein.

Applicants have amended claim 20 to delete reference to non-elected subject matter.

None of these amendments adds new matter.

#### Conclusion

Applicants request that the Examiner enter the above amendments, consider the accompanying remarks, and allow the pending claims to pass to issue.

Respectfully submitted,

Michael C. Badia

Registration No. 51,424

Agent for Applicants

Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, MA 02139-4242 Tel.: (617)444-6467

Fax.: (617)444-6483

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

refects in the images include but are not limited to the items checked:	
□ BLACK BORDERS	
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES	
☐ FADED TEXT OR DRAWING	
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING	•
☐ SKEWED/SLANTED IMAGES	
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS	
☐ GRAY SCALE DOCUMENTS	
☐ LINES OR MARKS ON ORIGINAL DOCUMENT	
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY	

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.